在严重联合免疫缺陷（SCID）新生小鼠中进行人细胞的面部静脉注射。

Facial vein injection of human cells in severe combined immunodeficiency (SCID) neonatal mice.

作者信息

Pavathuparambil Abdul Manaph Nimshitha, Al-Hawwas Mohammed, Liu Liang, Liu Donghui, Hayball John, Zhou Xin-Fu

机构信息

School of Pharmacy and Medical Sciences, Sansom Institute, University of South Australia, Adelaide 5000, South Australia, Australia.

Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide 5000, South Australia, Australia.

出版信息

MethodsX. 2018 Oct 6;5:1281-1286. doi: 10.1016/j.mex.2018.10.006. eCollection 2018.

DOI:10.1016/j.mex.2018.10.006

PMID:30364590

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6197144/

Abstract

Intravenous injection is a standard procedure for delivering human stem cells and therapeutic agents. Currently, genetically modified severe combined immunodeficiency (SCID) mice are used for engraftment studies using human cells. SCID neonates have better integration and survivability of human cells compared to adult SCID mice, as their immune system will not be developed in the first few days after birth. However, intravenous injections in neonates are difficult. This protocol describes a reliable and reproducible method for injecting cells into the facial vein of P3/P4 (3 or 4 days post-birth) SCID neonates to study their engraftment. The injection was safe and well tolerated by the pups. Post-injection analysis revealed the distribution of tagged cells in different organs. Results suggest that this new method can serve as a pre-analysis for transplantation studies using human stem cells before animal model testing.

摘要

静脉注射是输送人类干细胞和治疗药物的标准程序。目前，基因改造的严重联合免疫缺陷（SCID）小鼠被用于用人细胞进行的植入研究。与成年SCID小鼠相比，SCID新生小鼠的人细胞整合和存活能力更好，因为它们的免疫系统在出生后的头几天不会发育。然而，给新生小鼠进行静脉注射很困难。本方案描述了一种可靠且可重复的方法，用于将细胞注射到出生后3或4天（P3/P4）的SCID新生小鼠的面静脉中，以研究它们的植入情况。注射对幼崽来说是安全的，且耐受性良好。注射后分析揭示了标记细胞在不同器官中的分布。结果表明，这种新方法可作为在动物模型测试之前使用人类干细胞进行移植研究的预分析。